Home › Trials › NCT06780150

Investigating the effects of ocrelizumab on neurofilament levels and patient satisfaction in multiple sclerosis

SurfSubQ - A Prospective Longitudinal Multicenter Observational Study to Investigate Neurofilament Light Chain Levels and Patient Satisfaction After Subcutaneous Ocrelizumab Administration in Persons With Multiple Sclerosis

Observational Hoffmann-La Roche · NCT06780150

This study is testing how the medication ocrelizumab affects certain markers in the blood and how satisfied people with multiple sclerosis feel about their treatment after a year.

Quick facts

Study typeObservational
Enrollment842 (estimated)
Ages18 Years and up
SexAll
SponsorHoffmann-La Roche Industry-sponsored
Drugs / interventionsocrelizumab, rituximab, ublituximab
Locations84 sites (Aachen and 83 other locations)
Trial IDNCT06780150 on ClinicalTrials.gov

What this trial studies

This observational study aims to evaluate the effects of ocrelizumab treatment on neurofilament light chain (NfL) levels and participant satisfaction after 12 months of therapy. Participants diagnosed with multiple sclerosis, including relapsing and primary progressive forms, will be assessed using a therapy administration satisfaction questionnaire. The study focuses on individuals receiving their first treatment with ocrelizumab subcutaneously, following local prescribing guidelines. By monitoring these outcomes, the study seeks to provide insights into the treatment's impact on both biological markers and patient experience.

Who should consider this trial

Good fit: Ideal candidates for this study are individuals diagnosed with multiple sclerosis who are starting their first treatment with ocrelizumab.

Not a fit: Patients who have previously received treatment with rituximab or ublituximab, or those participating in other interventional studies, may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could enhance understanding of how ocrelizumab affects both neurobiological markers and patient satisfaction, potentially improving treatment approaches for multiple sclerosis.

How similar studies have performed: While this study focuses on a specific treatment and patient satisfaction, similar studies have shown promising results in evaluating treatment effects in multiple sclerosis.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Diagnosis of MS
* RMS and PPMS participants diagnosed according to the McDonald criteria of 2017
* First treatment during the course of MS therapy with ocrelizumab SC according to the local prescribing information, regardless of the reason for starting treatment with ocrelizumab

Exclusion Criteria:

* Participation in interventional studies investigating DMTs for MS
* Prior or simultaneous participation in CONFIDENCE or MoOzaRt (ISRCTN55332718) non interventional study (NIS) at the same study site
* Prior treatment with rituximab (MabThera®) or ublituximab (Briumvi®)
* Severe psychiatric disability
* Pregnant women

Where this trial is running

Aachen and 83 other locations

+34 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Multiple Sclerosis
Last reviewed 2026-06-10 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.